Sacral Nerve Stimulation Market – Current Scenario and Future Growth Analysis by...

Sacral Nerve Stimulation Market – Current Scenario and Future Growth Analysis by 2025

35
0

Global Sacral Nerve Stimulation Market: Overview

Sacral nerve stimulation (SNS), also known as sacral neuromodulation, is a medical electric stimulation therapy. It involves subcutaneous implantation of programmable stimulator. Several studies have been performed using electric stimulation therapy to treat patients with urinary problems, fecal incontinence, among others. The U.S. Food and Drug Administration approved sacral nerve stimulation therapy for the treatment of fecal incontinence in March 2011. The exact mechanism of sacral nerve stimulation therapy involves contraction of pelvic muscle and sphincter, which causes bladder contraction that involuntarily releases urine. Contraindications of sacral nerve stimulation involves diathermy use and mechanical outlet obstruction. Safety and efficacy of sacral nerve stimulation have not been determined in cases such as bilateral stimulation, pregnant patents, fetus, delivery, etc. Different types of sacral nerve stimulation available include external devices and implantable sacral nerve stimulation devices.

View Report: https://www.transparencymarketresearch.com/sacral-nerve-stimulation-market.html

Sacral nerve stimulation is performed in two phases: evaluation phase and implant phase. Rise in chronic urinary diseases, increase in investment in research related activities, and technological advancements in the pharmaceutical & medical devices industry are anticipated to drive the global sacral nerve stimulation market during the forecast period. However, cost of sacral nerve stimulation devices is likely to restrain the global sacral nerve stimulation market. In 2016, Axonics Modulation Technologies announced the first in class rechargeable sacral nerve stimulation devices to manage fecal incontinence. Medtronic offers Interstim system is used to manage bladder and bowel control. As per InterStim sales analysis, more than 225,000 patients worldwide received sacral nerve stimulation for bladder and bowel control.

Global Sacral Nerve Stimulation Market: Key Segments

The global sacral nerve stimulation market is segmented based on type of nerve stimulation device, application, end-user, and geography. In terms of type of nerve stimulation device, the market is divided in implantable SNS device and external SNS device. Based on application, the sacral nerve stimulation market is categorized into urine incontinence, fecal incontinence, and other applications. In terms of end-user, the sacral nerve stimulation market is categorized into hospitals, ambulatory surgery centers, and others. Medtronic offered Interstim system includes lead placed parallel to sacral nerve, implantable neurostimulator, and patient programmer. Patient programmer is primarily used to set parameters of electric pulses. Education and awareness programs to make deeper adoption of sacral nerve stimulation technology is an imperative factor which is expected to boost the sacral nerve stimulation market during the forecast period.

Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40994

Based on geographic, the global sacral nerve stimulation market is segmented into five key regions: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is expected to account for a major share of the global sacral nerve stimulation market due to developed health care infrastructure and rise in number of patients with bowel disorders. Europe accounts for the second largest share of the sacral nerve stimulation market. India, China, and Japan are the most developing countries in Asia Pacific. These countries are expected to fuel the global sacral nerve stimulation market.

Global Sacral Nerve Stimulation Market: Key Players

Major players operating in the global sacral nerve stimulation market include Medtronic Inc., Axonics Modulation Technologies, Inc., Cogentix Medical, and Nuvectra Corporation.

LEAVE A REPLY

Bitnami